



JSC SERVIER ENTERS INTO AGREEMENT WITH TAISHO PHARMACEUTICAL CO., LTD. IN RUSSIA AND EAEU COUNTRIES FOR LUSEOGLIFLOZIN IN TREATMENT OF TYPE 2 DIABETES MELLITUS

Moscow, May 28, 2018 – JSC Servier is pleased to announce the signing of a strategic agreement with Taisho Pharmaceutical Co., Ltd. Under this agreement, Taisho grants Servier the exclusive rights for manufacturing, development, distribution, commercialization and promotion of Luseogliflozin hydrate (Luseogliflozin hereinafter) in Russia and Eurasian Economic Union. Servier will become the Marketing Authorization Holder.

Luseogliflozin is a drug with a new mechanism of action that selectively inhibits sodium-glucose cotransporter 2 (SGLT2). It lowers blood glucose levels by inhibiting reabsorption of glucose in the renal tubule, thus increasing urinary glucose excretion. Luseogliflozin is planning to be produced in Russia at Servier's manufacturing plant LLC Servier-RUS located in Moscow from Japanese API in oral tablet form of 2,5 mg and 5 mg with once-daily intake. Luseogliflozin is approved under the trade name of Lusefi® in Japan from 2014 for the treatment of type 2 diabetes mellitus with recommended doses of 2,5 mg and 5 mg and can be administered in monotherapy as well as in combination with a broad range of other drugs.

As a result of phase 3 clinical trials conducted in respect of type 2 diabetes patients, these trials confirmed that Luseogliflozin demonstrates an excellent effect of blood glucose improvement in monotherapy and in combined administration with the six existing types of oral hypoglycemic agents, and that the effect was maintained for 52 weeks without attenuation. At the same time, the studies confirmed Luseogliflozin's excellent safety profile. Furthermore, as a result of analysis of the secondary endpoints of both studies, Luseogliflozin was found to significantly improve the blood glucose levels when fasting and also lowering body weight.

The number of people strongly suspected to have diabetes only in Russia is currently estimated to be around 9 million. Through the marketing of Luseogliflozin in Russia and EAEU JSC Servier and Taisho Pharmaceutical hopes to provide a new diabetes treatment option to more patients.

Launch in Russia is expected in 2020.

This partnership is a great opportunity for Servier to extend available portfolio in diabetes mellitus type 2 treatment in Russia and the EAEU countries and provide patients with a new original, well-tolerated treatment with a favorable safety profile.

Taisho Pharmaceutical Co., Ltd.:

Taisho Pharmaceutical Co., Ltd. conducts research, development, manufacturing and marketing of over-the-counter (OTC) medicine, special health foods, food products, medical products, and hygiene products (self-medication business) as well as research, development, manufacturing and marketing of ethical pharmaceuticals (prescription pharmaceutical business). While leading the market with top-share OTC medicines including Lipovitan D, Pavulon, and RiUP, Taisho Pharmaceutical is enhancing its development capabilities for new prescription medicines. While

exploiting the synergy between these two businesses, it seeks to contribute to the realization of a healthier and more prosperous life that everyone desires.

For more information, please visit www.taisho.co.jp/en/